1. Continued…
DR. MARIE LACOMBE
Porsgrunn, Norway
4740143342  mariechimie@yahoo.co.uk
Curriculum Vitae
EDUCATION AND CREDENTIALS
PhD Research Degree in Chemistry – 2003, University of Nottingham, UK
Bachelor of Science (Honours) in Chemistry, 1999 – University of Ottawa, Canada
Project Management
Engineering
Chartered Chemist
Member of the Royal Society of Chemistry [MRSC]
Analysis: IR, UV, NMR, HPLC, MS, SDS page, X-Ray crystallography
Languages: French, English, C1 German, B1 Dutch and Norwegian
IT: MS Office Suite, EndNote, ChemSketch and ChemDraw; Aspen to complete initiatives.
PROFESSIONAL EXPERIENCE
YARA INTERNATIONAL ASA, Posgrunn, Norway
Analytical Scientist, 2012 to Present
Execute project management and design of pilot electrolyzer chloride removal (earning the
Yara Innovation Award in 2016) by electrochemistry, which led to the creation of two patent
applications at the Norwegian Patent Office. Derive and implement improvements of NPK
and calcium nitrate production through online analysis (pH, gas and dust emissions, chemical
composition of finished products). Perform emission tests in pilot plants and plants with
portable online FTIR and UV equipment. Perform statistic modeling to identify the root cause
of ammonia emissions and developing clear guidelines to reduce the emissions significantly
with cost effective measures.
KREATECH DIAGNOSTICS, Amsterdam, Netherland
Research Scientist, 2003 to 2012
Conceptualised and rolled out Pt (II) drug delivery systems and other systems for diagnostic
and therapeutic applications. Invented and introduced patent 2,590,176 at the Canadian
Patent Office (synthesis of tridentate ligand).
UNIVERSITY OF NOTTINGHAM, Nottingham, UK
Demonstrator in Undergraduate Teaching Laboratories, 2000 to 2002
Supervised and led course studies, managing laboratory operations of undergraduate
students to achieve curriculum objectives and modalities.
RESEARCH ACCOMPLISHMENTS
 Designed, safely synthesised (COSSH assessments), analysed and tested ditopic
(anionic and cationic) receptors for transition metal salts, for water purification (1999
– 2003)

2. DR. MARIE LACOMBE – Page 2 of 2
 Carried out research on The Non-Equilibrium Effects in the Propagation Reactions of
the Combustions of H2 and O2 and created a Fortran Programme (1995 – 1999)
PUBLICATIONS
1. Increased liver Uptake and Reduced Hepatic Stellate Cell Activation with a Cell-
Specific Conjugate of the Rho-kinase Inhibitor Y27632, Pharm Res (2011) 28:2045-
2054
2. Development of a Cell-Selective and Intrinsically Active Multikinase Inhibitor
Bioconjugate, accepted for publication in Bioconjugate Chemistry, March 2011
3. Reduction of fibrogenesis by selective delivery of a Rho-kinase inhibitor to hepatic
stellate cells in mice, recommended for publication in the Journal of Pharmacology
and experimental Therapeutics, March 2011
4. Reduction of Advanced Liver Fibrosis by Short-term Targeted Delivery of an
Angiotensin Receptor Blocker to Hepatic Stellate Cells in Rats, Hepatology,
51(3):942-52, March 2010
5. Intervention in growth factor activated signaling pathways by renally targeted kinase
inhibitors, Journal of Controlled Release, Volume 132, Issue 3, 18 December 2008,
Pages 200-207
6. Renal targeting of kinase inhibitors, International Journal of Pharmaceutics
Volume 364, Issue 2, 8 December 2008, Pages 249-257
7. Inhibition of Renal Rho Kinase Attenuates Ischemia/Reperfusion-Induced Injury, J
Am Soc Nephrol 19: 2086-2097, 2008
8. Cell-specific Delivery of a Transforming Growth Factor-beta Type I Receptor Kinase
Inhibitor to Proximal Tubular Cells for the Treatment of Renal Fibrosis, Pharm Res.
2008, 25(10):2427-39
9. RGD-avidin–biotin pretargeting to αv β3 integrin enhances the proapoptotic activity of
TNFα related apoptosis inducing ligand (TRAIL), Apoptosis, Springer US,
11.12.2007, vol. 13, no. 2, pp. 225-235
10. Local inhibition of liver fibrosis by specific delivery of a platelet-derived growth factor
kinase inhibitor to hepatic stellate cells, J Pharmacol Exp Ther. 2007 Jun;321(3):856-
65
11. Intracellular delivery of the p38 mitogen-activated protein kinase inhibitor SB202190
[4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] in renal tubular
cells: a novel strategy to treat renal fibrosis, J Pharmacol Exp Ther. 200
Oct;319(1):8-19
12. Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells:
development of novel RGD-equipped and PEGylated drug-albumin conjugates using
platinum(II)-based drug linker technology, Bioconjugate Chemistry (2006), 17, 1246-
1255
13. Rational design of RGD-ablumin conjugates for targeted delivery of the VEGF-R
kinase inhibitor PTK787 to angiogenic endothelium, ChemMedChem (2006), 11,
1200-1203
14. Design and synthesis of heteroditopic aza-thioether macrocycles for metal extraction.
New Journal of Chemistry (2006), 30(12), 1755-1767